Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Yazji Salim</u>					2. Issuer Name and Ticker or Trading Symbol Oncternal Therapeutics, Inc. [ONCT]								Check	k all applic Directo	able) `	g Pers	son(s) to Iss 10% O Other (s	wner
(Last) 12230 EI	`	irst) REAL, SUITE	(Middle) 230		3. Date of Earliest Transaction (Month/Day/Year) 07/28/2022								X	below) `		below) lical Officer		speeding
(Street) SAN DII			92130 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							Indivine)						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				Transaction te onth/Day/Y	Execution Date,		Transaction Disposed Code (Instr. 5)		ties Acquired (A) or d Of (D) (Instr. 3, 4 an		nd	5. Amou Securitie Beneficia Owned F	es Formally (D) (I) (I)		vnership n: Direct r Indirect estr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	,	Amount	(A) (D)	Pric	•	Transaction(s) (Instr. 3 and 4)				
Common Stock 07/28/				07/28/202	2022		A		82,500 ⁽¹⁾ A		\$0	.00	149,637			D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Code				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		D	. Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
				Code	v	(A)		Date Exercisable		xpiration late	Title	Amour or Number of Shares	r					
Stock Option	\$1.04	07/28/2022		A		55,000		(2)	0	7/28/2032	Common Stock	55,00	0	\$0.00	55,000)	D	

Explanation of Responses:

Remarks:

/s/Chase C. Leavitt, Attorneyin-fact

08/01/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} Represents an award of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. One half of the RSUs vest on July 3, 2023, and one half of the RSUs vest on January 3, 2024, subject to the Reporting Person's continued employment or service with the Issuer on each such date. All of the RSUs vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan).

^{2.} One half of the shares subject to the stock options vest on July 3, 2023 and one half of the shares subject to the stock options vest on January 3, 2024, subject to the Reporting Person's continued employment or service with the Issuer on each such date. All of the shares subject to the stock options vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan).